United Kingdom · Retail pharmacy · Brand-name
Chemist Click review
Splits its range into injections and tablets with an efficacy figure on each — “up to 22%” and “up to 12.4%” — and no prices.
Overview
Chemist Click organises its offer by route rather than by brand: “weight loss injections: Mounjaro | Wegovy” at “lose up to 22% of body weight,” and “weight loss tablets: Wegovy | Orforglipron | Semaglutide” at “lose up to 12.4% of body weight.” It also states “no GP referral needed” for both.
Those percentages are ceilings rather than averages. The controlled-trial figures behind these molecules are lower — 20.9% for tirzepatide at 72 weeks, 14.9% for semaglutide, and 11.1% for orforglipron at its top dose. Presenting a best case as the headline is common in this market but worth recognising.
No prices, consultation fee, clinician description, BMI criteria or cancellation terms are published. Delivery is described only as discreet and confidential.
Medications and supply
Brand-name, split by route of administration rather than by brand.
- Mounjaro (tirzepatide) injection
- Wegovy (semaglutide) injection and tablet
- Orforglipron tablet
- Semaglutide tablet
How the service works
- Consultation
- Online, with no GP referral needed.
- Eligibility
- Not stated. No BMI criteria published.
- Provider involvement
- Not stated in the sources we checked.
- Lab requirements
- Not stated in the sources we checked.
- Pharmacy fulfilment
- Not stated in the sources we checked.
- Shipping
- Discreet and confidential delivery; timing and cost not stated.
- Support services
- Not stated in the sources we checked.
What it costs
| Item | Published price | Notes |
|---|---|---|
| All medications | not published | — |
- Membership fee
- None stated.
- Medication fee
- Not published.
- Insurance
- Not stated in the sources we checked.
- HSA / FSA
- Not stated in the sources we checked.
- Cancellation
- A cancellation policy is linked but its terms are not stated on the page.
- Refunds
- Not stated in the sources we checked.
Pros
- Clear split between injectable and oral routes, which is how most people actually choose
- Offers the oral orforglipron alongside injections
- No GP referral required
Cons
- No prices published at all
- Headline percentages are ceilings, not trial averages
- No clinician involvement, BMI criteria or delivery timing described
Who it may suit
Someone comparing injectable against oral routes — who will need to get prices elsewhere.
Limitations
- UK market only
- The “up to” figures overstate what the trials found on average
Questions
Is “up to 22%” realistic?
It is a ceiling. The SURMOUNT-1 average for tirzepatide 15 mg was 20.9% at 72 weeks, and individual response varies widely. The tablet figure of “up to 12.4%” sits above orforglipron’s published 11.1% average at its top dose.
Sources
Everything on this page traces to one of the links below, retrieved on the date shown. Prices and programme terms in this market change without notice — confirm against the provider before you buy.
- 01Chemist Click — route-based range and efficacy claimsretrieved 2026-08-15